AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine whether Fludarabine in combination with cytarabine is more effective than high-dose cytarabine in post-remission therapy for patients with AML1-ETO acute myeloid leukemia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Changhai Hospital
• Treatments: Cytarabine; Fludarabine; Fludarabine phosphate; Vidarabine

Criteria

Inclusion Criteria:

• Clinical and laboratory diagnosis of AML1-ETO positive acute myeloid leukemia

• In status of complete remission after one to two courses of induction therapy with DA(Daunorubicin 60mg/m2/d for 3 days, cytarabine 100mg/m2/d for 5-7days) regimen

• ECOG (Eastern Cooperative Oncology Group) score: <2

Exclusion Criteria:

• Serious liver/ kidney dysfunction

• Cardiac function level: 2 above

• Female in pregnancy or lactation

• With serious infection diseases or other diseases